DOI QR코드

DOI QR Code

Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II

  • Received : 2016.01.25
  • Accepted : 2016.11.10
  • Published : 2017.07.01

Abstract

Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up ($-42.05{\pm}32.73mg/dL$ vs. $-34.23{\pm}31.66mg/dL$, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups ($-20.16{\pm}54.49mg/dL$ in 4 mg group and $-24.45{\pm}63.88mg/dL$ in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up ($-0.13%{\pm}1.21%$ in 4 mg group and $-0.04%{\pm}1.10%$ in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

Keywords

Acknowledgement

Supported by : Ministry of Health and Welfare, National Research Foundation (NRF), Chonnam National University Hospital Research Institute of Clinical Medicine

References

  1. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-1389.
  2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009. https://doi.org/10.1056/NEJM199610033351401
  3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357. https://doi.org/10.1056/NEJM199811053391902
  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. https://doi.org/10.1016/S0140-6736(02)09327-3
  5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307. https://doi.org/10.1056/NEJM199511163332001
  6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622. https://doi.org/10.1001/jama.279.20.1615
  7. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630. https://doi.org/10.1016/S0140-6736(02)11600-X
  8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504. https://doi.org/10.1056/NEJMoa040583
  9. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28. https://doi.org/10.1056/NEJMoa042378
  10. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. https://doi.org/10.1056/NEJMoa050461
  11. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080. https://doi.org/10.1001/jama.291.9.1071
  12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38. https://doi.org/10.1056/NEJMoa042000
  13. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565. https://doi.org/10.1001/jama.295.13.jpc60002
  14. Lee SW, Hau WK, Kong SL, et al. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study. Circ J 2012;76:2662-2672. https://doi.org/10.1253/circj.CJ-12-0325
  15. Natsuaki M, Furukawa Y, Morimoto T, et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: perspectives from the CREDO-Kyoto registry cohort-2. Circ J 2012;76:1369-1379. https://doi.org/10.1253/circj.CJ-11-1356
  16. Okada K, Ueda Y, Takayama T, et al. Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study. Circ J 2012;76:1197-1202. https://doi.org/10.1253/circj.CJ-11-0966
  17. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163:157-164. https://doi.org/10.1016/S0021-9150(01)00765-1
  18. Suh SY, Rha SW, Ahn TH, et al. Long-term safety and efficacy of Pitavastatin in patients with acute myocardial infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS]). Am J Cardiol 2011;108:1530-1535. https://doi.org/10.1016/j.amjcard.2011.07.009
  19. Hong YJ, Jeong MH, Ahn Y, et al. Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels. J Cardiol 2012;60:277-282. https://doi.org/10.1016/j.jjcc.2012.04.003
  20. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-3214. https://doi.org/10.1161/CIRCULATIONAHA.108.822791
  21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. https://doi.org/10.1056/NEJMoa0807646
  22. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006;13:123-129. https://doi.org/10.5551/jat.13.123
  23. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269-275. https://doi.org/10.5551/jat.E562
  24. Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011;75:1493-1505. https://doi.org/10.1253/circj.CJ-10-1281
  25. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-1892. https://doi.org/10.1007/s00125-006-0269-5
  26. Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T, Kohno M. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis 2010;212:131-138. https://doi.org/10.1016/j.atherosclerosis.2010.04.019
  27. Mita T, Nakayama S, Abe H, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig 2013;4:297-303. https://doi.org/10.1111/jdi.12032
  28. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009;119:2103-2111. https://doi.org/10.1161/CIRCULATIONAHA.108.843219

Cited by

  1. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up vol.18, pp.None, 2017, https://doi.org/10.1186/s12933-019-0969-z
  2. Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study vol.42, pp.10, 2017, https://doi.org/10.1016/j.clinthera.2020.07.013